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Obstructive sleep apnea (OSA) is inducing oxidative stress and consequently promotes systemic inflam-
mation and cardiovascular morbidity. The respective impact of obesity, sleep apnea and acute cardiovas-
cular events on the profile of inflammatory cytokines has not been extensively evaluated. We examined
the profile of circulating cytokines in a case-control study comparing nonobese or obese patients with or
without sleep apnea and with or without an acute cardiovascular event. Patients were assessed by sleep
studies and inflammatory (hs-CRP, Leptin, RANTES, MCP1, IL6, IL8, TNF-a) and anti-inflammatory (adipo-
nectin, IL1-Ra) cytokines profile. A cardiovascular phenotyping was performed including carotid intima-
media thickness, pulse wave velocity and 24 h blood pressure monitoring. In comparison with patients
without sleep apnea or without comorbidities, patients with the combination of an acute cardiovascular
event and pre-existing sleep apnea showed a higher burden of systemic inflammation with significant
increase in serum levels of hs-CRP, IL1-Ra, IL-8, IL-6, TNF-a, Rantes and sICAM. Rantes and sICAM serum
levels were independently associated with AHI after an acute cardiovascular event.
Serum levels of different inflammatory markers were significantly increased in patients with the com-
bination of sleep apnea and an acute cardiovascular event. Since these biomarkers could be associated
with worsened cardiovascular outcome, diagnosing and treating associated sleep apnea is potentially
important in patients after an acute cardiovascular event.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Obstructive sleep apnea (OSA) is a highly prevalent condition
characterized by repetitive narrowing or occlusion of the pharynx
causing intermittent hypoxia, repetitive arousals and sleep
deprivation. OSA is associated with cardiovascular morbidity and
mortality [1,2]. Several studies have demonstrated an association
between OSA and prevalent and incident stroke and coronary
artery disease, independent of age, sex and body mass index
(BMI) [3–6]. A variety of pathophysiological mechanisms are in-
volved in OSA’s cardiovascular complications, including increased
cardiovascular sympathetic tone, impaired regulation of coagula-
tion, impaired glucose metabolism and endothelial dysfunctionll rights reserved.
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key roles in the activation of these pathways [8].
Systemic inflammation is known to play a major role during all
stages of atherosclerosis, from initiation over progression until
rupture of atherosclerotic plaques [9]. Moreover, increased
circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6)
and tumor necrosis factor-a (TNF-a) are associated with worsened
cardiovascular outcomes [10,11]. However, there are discrepancies
between studies investigating the relationship between OSA and
systemic inflammation [12–15], that have been related to
population heterogeneity including variable degrees of cardiovas-
cular co-morbidities and obesity. Hence, uncertainty remains
about the direct impact of OSA on circulating inflammatory medi-
ators. Besides, it is also unknown whether the occurrence of an
acute cardiovascular event associated with pre-existing OSA may
magnify the inflammatory response.
Therefore using serum levels of high sensitive CRP (hs-CRP),
IL1-Ra, IL-6, IL-8, TNF-a, MCP-1, Rantes, Adiponectin, Leptin, and
sICAM, we aimed to identify inflammatory profiles of patientsokines: Impact of OSA, obesity and acute cardiovascular events. Cytokine
2 D. Testelmans et al. / Cytokine xxx (2013) xxx–xxxdepending upon the association of acute cardiovascular event
(acute coronary syndrome (ACS) or cerebrovascular event), OSA
and obesity. Patients were further characterized by carotid inti-
ma-media thickness (IMT), pulse wave velocity (PWV) and 24 h
blood pressure monitoring. We hypothesized that systemic inflam-
mation is increased in OSA patients with an acute cardiovascular
event in comparison with patients without such an event or pa-
tients with an acute cardiovascular event but without OSA.
2. Methods
2.1. Study design
This study was a case-control study at CHU Grenoble in which
inflammatory profiles of five patient groups were evaluated. Ethi-
cal approval was obtained from our institutional review board (Co-
mité de protection des personnes Sud-Est V) and all subjects gave
written informed consent.
2.2. Study population and assessment
Patients and healthy subjects were recruited to complete five
groups: (1) healthy control group (n = 15); (2) non-obese OSA group
(n = 15); (3) acute cardiovascular event group without OSA (CV)
group (n = 12); (4) acute cardiovascular event group with OSA
(CV-OSA) group (n = 15) and (5) obese-OSA group (n = 15). Non-ob-
ese patients and healthy control subjectswere selected according to
age and BMI, in order to achieve similar age and BMI between
groups. Controls and OSA patients were free of history of cardiovas-
cular disease, while patients in the CV and CV-OSA group were in-
cluded during the first week of an ACS or a cerebrovascular
ischemic accident. Patients in the obesity group were all eucapnic
during daytime. All patients underwent clinical assessment; blood
samples were taken and overnight polysomnography and PWV
measurement were performed. In all groups, except the obesity
group, 24-h ambulatory blood pressure monitoring and carotid
IMT measurement were done. Table 1 shows an overview of the
measurements performed in the different groups.
2.3. Polysomnography
Overnight full polysomnographies into our sleep center were
performed in all study patients during spontaneous breathing in
order to characterize abnormal respiratory events during sleep.
Sleep and respiratory events were recorded and scored manuallyTable 1
Overview of measurements in study groups.
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sleep studies were scored by technicians and validated by the staff
physician. Arousals were scored using standard criteria [17]. Hyp-
opneas were scored upon the presence of an arousal if decrease in
flow were between 30% and 50% without significant drop in SpO2.
The classification of hypopneas as obstructive or central was based
on the thoraco-abdominal band signal, the pulse transit time sig-
nal, and the shape of the respiratory curve of nasal pressure (flow
limited aspect or not) [16,18]. Diagnosis of OSA required an apnea/
hypopnea index (AHI) of 15 or more events per hour. In patients
with an acute cardiovascular event, PSG was performed after two
months of evolution to minimize the possible presence of periodic
breathing that could accompany acute cardio- or cerebrovascular
events.
2.4. Biomarkers of systemic inflammation
Fasting morning blood samples were drawn two to three days
after the acute cardiovascular event (CV groups) or after the sleep
recording night in the other groups. Serum hs-CRP level was mea-
sured using automated immunonephelometry (Behring Nephe-
lometer II Analyzer, Dade Behring, Germany). Leptin, CCL5/
RANTES (Regulated upon activation normal T-cell expressed an se-
creted), CCL2/MCP1 (Monocyte chemo-attractant protein 1), IL-6,
IL-8, TNF-a, Adiponectin, sICAM (not in obese group) and IL-1Ra
were measured by multiplex beads immunoassays (Fluorokine
MAPMultiplex Human Cytokine Panel and Obesity Panel, R&D Sys-
tems, Minneapolis, USA) and read by the Bioplex 200 array reader
(Bio-Rad Laboratories, Hercules, USA) which uses Luminex xMAP™
Technology (Luminex Corporation, Austin, USA).
2.5. Vascular evaluation
Ambulatory blood pressure was measured in the dominant arm
over 24 h at 15-min intervals (ABP monitor 90207; Spacelabs
Healthcare, Issaquah, WA, USA). Blood pressure acquisition began
at 09:00 h and ended 24 h later. Arterial stiffness was determined
by carotid-femoral PWV using a noninvasive device (Complior

, Ar-
tech Medical, Pantin, France). Common carotid artery and femoral
artery pressure waveforms were recorded. The distance between
the two recording sites (D) was measured and PWV was automati-
cally calculated as PWV = D/t, whereas (t) is the pulse transit time
[19]. Carotid IMTwas evaluated using B-mode ultrasonography per-
formed using a HP Sonos 2500 (Hewlett Packard) with a sectorial
7.5 MHz probe. The method used to determine the mean commonokines: Impact of OSA, obesity and acute cardiovascular events. Cytokine
Table 2
Patient characteristics.
Controls CV CV-OSA Non-obese OSA Obese-OSA X2
N 15 12 15 15 15
Age (years) 48 ± 6 53 ± 9 53 ± 9 52 ± 8 52 ± 10
Male (%) 53 83 93 80 33# <0.05
Body mass index (kg/m2) 24 ± 3 25 ± 3 25 ± 4 25 ± 3 43 ± 6##
Abdominal circumference (cm) 84 ± 9 90 ± 10 94 ± 15 88 ± 11 125 ± 10##
Diabetes (%) 0 0 0 0 20 NS
Hypertension (%) 7 83 87 7 60 <0.001
Beta-blocker (%) 0 58 60 0 13 <0.001
ACE-I/AT2-AT (%) 0 67 60 0 20 <0.001
Diuretics (%) 0 25 7 0 20 NS
Smoking
Former (%) 13 50 20 13 47 NS
Current (%) 7 42 53 20 20 <0.05
Dyslipidemia (%) 67 58 80 80 87 NS
Statin (%) 0 33 20 0 13 <0.05
ACS (%) 0 67 60 0 0 <0.001
CVA (%) 0 33 40 0 0 <0.001
Dyslipidemia: statin or TC > 190 mg/dL or LDL > 115 mg/dL; ACS: Acute coronary syndrome; CVA: cerebrovascular accident.
⁄p < 0.05 vs. control; ⁄⁄p < 0.01 vs. control and SAS; p < 0.01 vs. other groups; #p < 0.05 vs. CV-SAS; ##p < 0.001 vs. other groups.
D. Testelmans et al. / Cytokine xxx (2013) xxx–xxx 3carotid IMT and luminal diameter has been previously described
[20]. Both common carotid arteries were studied consecutively in
the long axis with a probe incidence allowing good quality images.
The images were recorded in end-diastole and then analyzed by
specific validated software (TIMC laboratory, Grenoble, France).
IMT and diameter measurements were carried out on areas free of
atheroma and then averaged. The IMT and luminal diameter values
for any given subjectwere themean values for the two common car-
otid arteries. Ultrasonographywas performed by two operators who
were blinded to the other study data. The analysis of carotid param-
eters using the specific software was performed by the same oper-
ator throughout the entire study. Vascular evaluation was
performed two to three days after the acute cardiovascular event
or after the sleep recording in the other groups.2.6. Statistical analysis
Data were reported as mean ± standard deviation (SD) or med-
ian [interquartile range], when appropriate. Proportions were ex-
pressed in percentage (%). Comparisons between groups were
performed using Anova or Kruskal–Wallis test. When significance
was achieved, the appropriate test (Tukey’s or Dunns test) was
used for post hoc analysis. Categorical variables were tested using
Fisher exact test. Correlations were assessed by using Spearman
test. Multivariate analysis was performed to identify variables that
were independently associated with inflammatory parameters.Table 3
AHI and vascular parameters.
Controls CV
AHI (events/h) 8 ± 5 9 ± 4
Meansat (%) 95 ± 2 96 ± 3
Minsat (%) 89 ± 2 88 ± 6
Office SBP (mmHg) 127 ± 11 126 ± 23
Office DBP (mmHg) 87 ± 8 73 ± 11
Heart rate (beats/min) 64 ± 9 58 ± 12
PWV (m/s) 8.8 ± 0.9 10.9 ± 2.9
Carotid IMT (mm) 0.60 ± 0.07 0.67 ± 0.12
Mean SBP during 24 h (mmHg) 122 ± 8 122 ± 22
Mean DBP during 24 h (mmHg) 81 ± 7 74 ± 13
Mean PP during 24 h (mmHg) 41 ± 6 48 ± 11
** p < 0.001 vs. controls and CV.
 p < 0.001 vs. controls and non-obese OSA.
# p < 0.05 vs. controls and obese-OSA.
§ p < 0.001 vs. others.
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regression model. Results were considered significant when
p-values were <0.05.
During the evaluation of the CRP-data, we found two outliers in
the CV-OSA group. Analysis with or without these measurements
did not result in changes of the significant differences between
groups, so we included these measurements in our analyses.3. Results
3.1. Patient characteristics (Table 2)
Age was comparable in all groups as expected owing to the
study design. BMI and abdominal circumference were similar in
the healthy controls, non-obese OSA group, CV group and CV-
OSA group while by design being higher in the obese-OSA group.
In the CV and CV-OSA groups, the proportion of patients who
smoked or were suffering from arterial hypertension was higher
in comparison with the control and OSA groups. According to
groups definition, AHI was significantly higher in the OSA, CV-
OSA and obese-OSA groups compared to control and CV groups
while no difference was found in AHI between the latter two
groups (Table 3). However, mean and minimal oxygen saturation
during sleep were significantly lower in the obese-OSA group,
which highlights that nocturnal hypoxia is clearly linked to
obesity.CV-OSA Non-obese OSA Obese-OSA
36 ± 19** 38 ± 15** 45 ± 30**
95 ± 3 94 ± 2 91 ± 2§
86 ± 5 86 ± 4 75 ± 9§
125 ± 21 131 ± 9 132 ± 11
77 ± 14 85 ± 9 84 ± 8
61 ± 9 66 ± 12 NA
11.2 ± 3.5# 9.5 ± 1.5 8.8 ± 1.4
0.71 ± 0.21 0.68 ± 0.18 NA
120 ± 16 122 ± 14 NA
75 ± 10 79 ± 9 NA
45 ± 8 43 ± 10 NA
okines: Impact of OSA, obesity and acute cardiovascular events. Cytokine
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As expected, PWV was significantly different between groups
(Anova p < 0.01), due to a lower value in the control group com-
pared to the CV-OSA group (p < 0.05). Office diastolic blood pres-
sure was significantly lower in the CV groups in comparison with
the control and OSA groups. There was no difference in 24 h blood
pressure and carotid IMT between groups.
3.3. Inflammatory profile
3.3.1. Effect of acute cardiovascular event in patients without OSA
Comparing patients of the CV group with healthy controls, both
hs-CRP (5.6 [1.9–13.9] vs. 1.0 [0.6–1.7] mg/L) (p < 0.05) and IL1-Ra
(1694 [1258–2568] vs. 788 [464–1097] pg/mL) (p < 0.05) levels
were higher.
3.3.2. Effect of OSA in nonobese subjects
Comparing the non-obese OSA group with healthy controls, no
significant difference was found between levels of hs-CRP, IL-1Ra,
IL-8, TNF-a, sICAM, IL-6, Rantes, Adiponectin, Leptin or MCP1
(Fig. 1).
3.3.3. Effect of obesity
Comparing patients with or without obesity having similar de-
gree of OSA severity, TNF-a (2.4 [1.7–2.9] vs. 1.6 [1.0–2.1] pg/mL,
p < 0.05), hs-CRP (4.3 [2.3–8.7] vs. 0.7 [0.4–1.2] mg/L; p < 0.01)
and Leptin (91.6 [53.1–154.5] vs. 3.6 [2.4–8.1] pg/L; p < 0.001) ser-
um levels were higher in the obese-OSA group. However, IL1-Ra,Fig. 1. Boxplots of serum levels of hs-CRP (mg/L), sICAM (lg/dL), Rantes (gg/mL), Leptin
Ra (gg/cL) in healthy control group, CV group, OSA group, CV-OSA group and obese-OSA
for CV-OSA group and obese-OSA group vs. non-obese OSA group).
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in these two groups (Fig. 1).
3.3.4. Effect of acute cardiovascular event in OSA patients
Comparing patients from the CV-OSA group and non-obese OSA
group having a similar age, BMI and OSA severity, a marked inflam-
matory response was found in the CV-OSA group. With the occur-
rence of an acute cardiovascular event, hs-CRP (7.0 [2.6–9.6] vs. 0.7
[0.4–1.2] mg/L; p < 0.001), IL1-Ra (1939 [1149–2360] vs. 600 [406–
695] pg/mL; p < 0.001), IL-8 (17.8 [6.9–141.7] vs. 5.9 [4.0–7.9] pg/
mL; p < 0.01), TNF-a (2.5 [2.0–3.1] vs. 1.6 [1.0–2.1] pg/mL;
p < 0.05), Rantes 48.1 [37.6–65.1] vs. 35.3 [28.2–44.1] gg/mL;
p < 0.05) and sICAM (219 [208–252] vs. 185 [169–204] ng/mL;
p < 0.05) were increased (Fig. 1). Moreover, the proportion of IL-6
levels above the cut-off of 1.5 pg/mL was higher in the CV-OSA
vs. non-obese OSA group (p < 0.0001).4. Correlations between clinical characteristics, sleep
parameters and inflammatory and vascular markers (Table 4)
As expected, age was correlated with vascular stiffness and car-
otid IMT. OSA severity correlated also with the vascular parame-
ters. In addition, significant correlations were found between the
level of some of the inflammatory and vascular parameters. In
the subgroup of patients with acute cardiovascular event, sICAM
(r = 0.41) and Rantes (r = 0.45) were significantly correlated with
AHI (Figs. 2 and 3). Multivariate analysis showed that in patients
with acute cardiovascular event, higher Rantes and sICAM levels
were independently associated with AHI (R2 = 0.37).(gg/mL), Adiponectin (gg/mL), TNF-a (qg/cL), MCP-1 (gg/dL), IL-8 (qg/mL) and IL1-
group. Grey color means significant difference (for CV group vs. healthy control and
okines: Impact of OSA, obesity and acute cardiovascular events. Cytokine
Table 4
Univariate correlations between clinical, sleep, inflammatory and vascular
parameters.
PWV p IMT p PP24 p
Age 0.54 0.0001 0.49 0.0002 0.36 0.006
AHI 0.29 0.03 0.36 0.007 0.23 0.08
Minsat 0.07 0.63 0.27 0.046 0.14 0.30
CRP 0.41 0.002 0.2 0.14 0.03 0.81
IL1ra 0.22 0.1 0.15 0.28 0.28 0.04
TNFa 0.28 0.04 0.02 0.86 0.10 0.47
sICAM 0.29 0.03 0.37 0.005 0.53 0.0001
Adiponectin 0.02 0.90 0.10 0.50 0.31 0.02
AHI: apnea/hypopnea index; Minsat: minimal saturation during the PSG; PWV:
pulse wave velocity; IMT: intima-media thickness; PP24: mean pulse pressure
during 24 h.
Fig. 2. Correlation between Rantes serum levels and AHI in patients after an acute
cardiovascular event (CV and CV-OSA groups).
Fig. 3. Correlation between sICAM serum levels and AHI in patients after an acute
cardiovascular event (CV and CV-OSA groups).
Table 5
Inflammatory profiles.
CRP TNF-a IL1-b IL-8 sICAM Rantes Leptin
OSA – – – – – – –
Ob-OSA % % – – NA – %
cv-OSA % % % % % % –
CV % – % – – – –
CV and OSA: in comparison with healthy controls.
Ob-OSA and CV_OSA: in comparison with OSA.
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We evaluated inflammatory profiles based on serum cytokines
and hs-CRP in five dedicated subgroups depending upon the pres-
ence or not of OSA, obesity and recent cardiovascular events. We
have cautiously phenotyped these groups using 24 h blood pres-
sure, PWV, and IMT as surrogate markers of the cardiovascular risk.
The major findings of our study are as follows: (i) inflammatory
markers were not elevated in non-obese OSA patients withoutPlease cite this article in press as: Testelmans D et al. Profile of circulating cyt
(2013), http://dx.doi.org/10.1016/j.cyto.2013.02.021co-morbidities, (ii) an acute cardiovascular event in patients with
OSA leads to an increased burden of inflammatory profile, (iii) in
contrast only some biomarkers were increased after an acute car-
diovascular event in patients free of OSA. Interestingly this profile
remains different fromwhat is seen in obese OSA patients with sta-
ble cardiovascular disease (Table 5). (iv) Finally, potentiation be-
tween OSA and acute cardiovascular event is likely to involve
Rantes and sICAM as these two markers are correlated with OSA
severity.
5.1. Inflammatory markers and cardiovascular disease
Circulating inflammatory markers have been extensively inves-
tigated in cardiovascular disease. Indeed, these markers have been
found to be key factors in cardiovascular conditions related to ath-
erosclerosis [9] – high expression during acute cardiovascular
events being correlated with poorer prognosis – and useful predic-
tors of future events in asymptomatic patients [21–24]. In a large
systematic review, long-term IL-6 levels were shown to be associ-
ated with the risk of coronary heart disease [25]. TNF-a expression
in atherosclerotic plaques was associated with remodeling and was
shown to facilitate plaque rupture and thrombus formation
[26,27]. Moreover, in asymptomatic men, hs-CRP proved to be an
independent predictor of future myocardial infarction and stroke
[28].
5.2. Effect of OSA and obesity on inflammatory markers
Previous, non-randomized, trials have reported increased levels
of inflammatory cytokines in OSA patients that could be reduced
by using CPAP. In the single RCT evaluating CRP evolution when
treated by effective vs. sham CPAP no difference was found in ob-
ese OSA [13]. Accordingly, some authors could not confirm the in-
crease in systemic inflammation in patients with OSA [12]. In this
study, we did not find a significant increase in systemic inflamma-
tory markers in non-obese OSA patients free of co-morbidities. The
presence of a lower proportion of males in the control group could
possibly contribute to these findings since it is known that several
inflammatory cytokines (e.g. hs-CRP, IL1-Ra, Leptin, etc.) are higher
in women than in men [29–31]. Hence, we cannot rule out that
OSA per se does activate pro-inflammatory pathways, but OSA
may have less effect compared to other cardiovascular risk factors
including obesity and physical activity. When OSA was associated
with obesity, there was a change in the inflammatory profile with
an increase in hs-CRP and TNF-a. In addition, an increase in Leptin
level was typically found as expected in obese patients [32]. How-
ever, as the proportion of females is higher in the obese-OSA group
in comparison with the non-obese groups, the increase in hs-CRP
and Leptin levels could possibly be overestimated due to a gender
effect [29,31].
5.3. Inflammatory markers after an acute cardiovascular event
The findings in the CV-groups (OSA+ and OSA) corroborate
previous studies looking at inflammatory responses related to anokines: Impact of OSA, obesity and acute cardiovascular events. Cytokine
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rable with the levels shown by Schaub et al. [33]. Also, Rantes and
TNF-a levels in OSA and after an acute cardiovascular event are
comparable with the levels demonstrated in previous publications
[22,34–36]. Furthermore, IL-8 and sICAM levels in our OSA group
are comparable with those published by Al Lawati et al. [37].
However, to date, no data have been reported looking at the
combined effect of OSA and acute cardiovascular events. Although
in the absence of OSA, an acute CV event was characterized by an
increase in hs-CRP and IL1-Ra, an anti-inflammatory cytokine,
whilst the association of OSA and acute CV event was characterized
by increased serum levels of hs-CRP, IL1-Ra, IL-8, TNF- a, Rantes,
sICAM and IL-6.
As previously shown, Rantes is involved in the intermittent hy-
poxia-induced development of systemic inflammation and inflam-
matory pre-atherosclerotic remodeling [38]. Rantes plasma levels
rose transiently during severe ischemic symptoms in patients with
unstable angina pectoris [34]. We also previously evidenced that
increased systemic Rantes levels were present in obesity hypoven-
tilation patients in comparison with eucapnic obese patients [39].
On the other hand, Rantes levels remained unchanged after
3 months of CPAP treatment in severe, obese OSA patients [40].
In our study, Rantes was not elevated in patients with OSA free
of acute cardiovascular event. However the combination of OSA
and acute cardiovascular event led to a significant increase. The
mechanisms behind this up-regulation of Rantes cannot be deter-
mined from this study. After multivariate analysis, Rantes level re-
mained independently associated with OSA severity in the group
OSA plus acute cardiovascular event.
Also, sICAM levels were shown to reflect vascular inflammation
and found associated with adverse events in patients with cardio-
vascular disease [41]. Circulating sICAM levels were increased in
moderate to severe OSA patients and these levels correlated with
AHI in patients with coronary artery disease [42,43]. Chin et al.
demonstrated a significant decrease in sICAM after 1 month of
CPAP treatment in OSA patients [44]. In our study, sICAM was ele-
vated in patients presenting with acute cardiovascular event and
OSA and sICAM levels were independently associated with OSA
severity in these patients.
5.4. Vascular parameters in sleep apnea and atherosclerosis
Subclinical markers of vascular pathology, including carotid
IMT, carotid-to-femoral PWV and pulse pressure are well validated
and used for assessing cardiovascular risk and prognosis [45,46]. In
agreement with other reports, AHI was significantly correlated
with PWV and carotid IMT, however after multivariate analysis
only an independent association with carotid IMT remained
[47,48]. Our findings of increased inflammatory markers in OSA pa-
tients after acute cardiovascular event, contributes to the growing
body of evidence that OSA should be evaluated in these patients.
Since higher levels of inflammatory markers could be associated
with a worsened cardiovascular prognosis, treating concomitant
OSA could be important regarding cardiovascular outcomes in
these patients. Nevertheless, this should be examined in future,
prospective studies.
5.5. Limitations of the study
Since study groups were rather small, the possibility that differ-
ences in the systemic inflammatory levels between the control and
OSA group would have been missed cannot be excluded. In order to
achieve statistical significance with the difference we found be-
tween healthy subjects and OSA patients, a sample size of more
than 29 for both categories would be required for sICAM, more
than 83 in each for both categories would be required for TNF-a.Please cite this article in press as: Testelmans D et al. Profile of circulating cyt
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be more than 220 for sICAM, 34 for Rantes and 334 for TNF-a. In
order to achieve statistical significance with the difference we
found between healthy subjects and patients with acute cardiovas-
cular events and no OSA a sample size of more than 22 for both cat-
egories would be required for TNF-a. Accordingly, to reject
equivalence, the sample size then should be more than 29 for sI-
CAM, 21 for Rantes and 43 for TNF-a. Our groups were matched
on age and BMI but not for gender. This led to a lower proportion
of males in the control and Obese-OSA groups compared to other
groups; however, this only reached significance between the Ob-
ese-OSA and CV-OSA groups. This is of interest since gender may
have an effect on cytokine levels. Compared to males Leptin, hs-
CRP and IL1-Ra levels have been reported to be higher in women
[29–31]. For TNF-a, lower circulating levels were described in fe-
males in comparison with males [49]. To this extent, differences
may have been masked or overestimated due to gender effect for
control and Obese-OSA groups (see above). Future studies account-
ing for cytokine levels in this population should take into account
gender effects or be perfectly matched for gender. Nevertheless, we
clearly showed that the degree of systemic inflammation after an
acute cardiovascular event in patients with OSA was much higher.
Also, chemokines were only measured at admission, and serial
measurements were not obtained. This remains to be done in fu-
ture studies. Furthermore, the BMI in the non-obese groups with
OSA is low and therefore maybe not totally comparable with the
OSA population in general. However, matching was performed
for BMI to eliminate the confounding effect of obesity on the cyto-
kine profile.6. Conclusion
This study showed that the presence of sleep apnea in patients
presenting with an acute cardiovascular event was associated with
a significant increase in the serum levels of different inflammatory
markers. Future studies should focus on whether these inflamma-
tory markers are linked with worsened cardiovascular prognosis
and whether treatment of the underlying sleep apnea leads to
improvement of cardiovascular outcomes.
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